CTIS2023-504731-40-01招募中1 期
EMPagliflozin after Aortic Valve Replacement - the EMPAVR study - a randomized clinical trial - 2023-504731-40-00
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 206
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Severe symptomatic AS AND Surgical or transcatheter AVR within 14 days
排除标准
- •Prior treatment with an SGLT2i, LVEF <45%, eGFR <30ml/min, Hypersensitivity to empagliflozin or placebo tablet
研究者
相似试验
已完成
4 期
EMPagliflozin After Aortic Valve ReplacementAortic Valve StenosisNCT06171802Rigshospitalet, Denmark206
已完成
4 期
Dapagliflozin After Transcatheter Aortic Valve ImplantationTranscatether Aortic Valve ImplantationAortic StenosisNCT04696185Spanish Society of Cardiology1,257
已完成
不适用
Mid-term results of surgical aortic valve replacement with bioprostheses in hemodialysis patientsaortic stenosisJPRN-UMIN000047410Dokkyo Medical University School of Medicine57
已完成
不适用
Anticoagulation following tissue aortic valve replacementAortic valve diseaseCirculatory SystemISRCTN51663857St George's Healthcare NHS Trust (UK)400
招募中
不适用
Surgical Replacement and Transcatheter Aortic Valve Implantation Trial 10 Year Follow-upsevere aortic valve stenosis10046973NL-OMON45149Medtronic B.V.160